After completing his PhD in Molecular Biology (Grenoble, 1986), Dr. Allibert acquired his first experience in Human Diagnostic with bioMérieux. During the 15 years he spent with this company, he was the pioneer of the Molecular Biology deployment in this company by successfully launching the first HLA-DR test based on molecular methods for bone marrow and graft transplantation. Dr. Allibert then worked 5 years with another biotech company in the animal Health domain (Merial) as Corporate Director for BioAnalytical Development, leading R&D teams both in France and US. He was located in the Atlanta area and played a key role in the launch of new animal vaccines. In 2006 he joined BD Diagnostics as Vice President R&D Molecular in Québec. Dr. Allibert was in charge of developing multiple tests and technologies to cover the increasing needs for the Health Acquired Infections (HAI). He was also instrumental in the installation of BD Diagnostics in Quebec.
In 2011 and 2012, Dr. Allibert moved to his new role as Vice President Strategic Innovation for Molecular Infectious Diseases. He is now CEO at GenePOC Inc., a company located in Québec which develops DNA based microfluidic devices which allow the rapid diagnostic of infectious diseases at Point Of Care Between 1998 and 2001 Dr. Allibert acted as an expert for the European Community (Genomic and Proteomic domains) and was involved in the EU Program V. He is now a member of the Institute Advisory Board of the CHIR Institute of Infection and Immunity.